What's New in CIDP Treatment in 2026: A Patient Guide

CIDP, short for chronic inflammatory demyelinating polyneuropathy, is a rare autoimmune condition where the immune system damages myelin, the protective coating around peripheral nerves. In daily life, it shows up as common symptoms: weakness climbing stairs, numbness in the hands or feet, difficulty with small movements like buttoning a shirt, and persistent fatigue.

For decades, CIDP treatment options stayed the same: immunoglobulin therapy, plasma exchange, or steroid medications. In 2024, two newer therapies received FDA approval, adding genuinely new choices, including one that takes less than two minutes a week at home. This guide covers what is available in 2026, what each option involves, and how the newer therapies fit alongside the established standards.

Standard treatments doctors still use in 2026

For most people with CIDP, treatment begins with one of several long-established therapies. Around six to eight people out of every ten respond well to one of them. The right choice depends on the disease pattern, severity, and individual response. A complete overview of available CIDP treatment options covers each in greater detail.

Intravenous immunoglobulin (IVIG)

IVIG for CIDP is the most commonly prescribed first-line treatment. It uses antibodies pooled from thousands of healthy donors to calm the immune attack on the nerves.

• Best suited for: newly diagnosed CIDP and most adult cases as first-line therapy.
• Route: IV infusion through a vein.
• Each session: several hours, typically in a hospital or infusion center; home infusion is available for some patients depending on insurance.
• Loading dose: given over two to five days at the start of treatment.
• Maintenance schedule: roughly every three weeks, adjusted to the patient's response.
• When improvement shows: within one to two weeks initially; the full effect builds over several months.
• Common side effects: headache, fatigue, low-grade fever, chills, and an occasional wash-out feeling for a day or two after infusion; usually eased by hydration, slower infusion rates, and pre-medications.

More on managing IVIG side effects covers what to watch for and how to ease the impact.

Subcutaneous immunoglobulin (SCIg)

Subcutaneous immunoglobulin uses the same donor-derived antibodies as IVIG but delivers them as small injections placed just under the skin, rather than into a vein.

• Best suited for: patients who want fewer clinic visits, have difficulty with venous access, or prefer to manage treatment at home.
• Route: subcutaneous injections, self-administered at home after training with a specialty nurse.
• Each session: around an hour.
• Schedule: typically weekly.
• Advantages over IVIG: shorter sessions, fewer clinic hours, and fewer systemic side effects such as headache and fatigue.
• Trade-off: more frequent dosing schedule (weekly versus every three weeks).
• Common side effects: local skin reactions including redness, swelling, and a small lump under the skin that flattens within a day.

Plasma exchange (plasmapheresis)

Plasma exchange is a procedure, not a medicine. A specialized device separates the plasma carrying the harmful antibodies, replaces it with substitute fluid, and returns the blood to the body.

• Best suited for: severe CIDP relapse where rapid improvement is needed.
• Course: five to ten sessions over two to four weeks.
• Setting: hospital or specialty clinic (specialized equipment is required).
• Onset of benefit: sometimes within days.
• Limitation: benefit fades within weeks unless followed by another maintenance treatment.

Steroid medications

Steroid medications such as prednisone work by calming the broader immune system. They are inexpensive, widely available, and effective for many people, particularly in early disease.

• Best suited for: early-disease cases, severe relapses needing quick control, or as a bridge to another treatment.
• Forms: daily oral tablets, high-dose oral pulses spaced weeks apart, or IV in severe cases.
• Dosing strategy: higher dose to gain control, then tapered to the lowest effective level.
• Short-term side effects: appetite changes, mood swings, insomnia, raised blood sugar.
• Long-term side effects: weight gain, bone thinning, increased infection risk, cataracts, easy bruising.
• Common practice: used briefly to bridge to another treatment, or long-term at the lowest dose that maintains control.

Other immunosuppressants

When first-line therapies do not deliver enough benefit, doctors may add medications that lower immune activity more broadly. None are FDA approved specifically for CIDP, but each has a long history of use across autoimmune diseases.

• Best suited for: treatment-resistant cases, or as steroid-sparing additions to reduce long-term steroid exposure.
• Common choices: azathioprine, mycophenolate, methotrexate, and cyclophosphamide.
• Use pattern: usually combined with IVIG or steroids to reduce the partner drug's dose or extend the gap between infusions.
• Onset: weeks to months.
• Monitoring: regular blood tests for liver, kidney, and bone marrow function.

Across all the standard options, the broad picture is the same: most newly diagnosed patients begin with IVIG, plasma exchange, or steroids. SCIg and the other immunosuppressants typically come into the conversation later, either as a way to make treatment easier to live with or to manage cases that do not respond well enough to the initial therapy.

What's new in CIDP treatment as of 2026

The standard CIDP treatments looked much the same year to year for over three decades. In 2024, two newer therapies received FDA approval and shifted that picture. One is a refined way of delivering immunoglobulin under the skin. The other is the first medicine with a new mechanism of action approved for CIDP in over thirty years. Both are now available in the United States, and both can be taken at home after appropriate training.

Hyaluronidase-facilitated subcutaneous immunoglobulin

The first 2024 approval was a new way of delivering subcutaneous immunoglobulin. It combines a 10% concentration of donor antibodies with an enzyme called recombinant human hyaluronidase. The enzyme briefly loosens the connective tissue under the skin, which allows a much larger volume of immunoglobulin to be absorbed in a single session.

• Best suited for: adults whose CIDP is already controlled on IVIG and who want fewer infusion sessions per month.
• Approval: maintenance therapy, not initial treatment.
• Route: subcutaneous infusion under the skin.
• Schedule: every two, three, or four weeks (up to once a month).
• Each session: longer than standard SCIg because a larger volume is given, but spaced much further apart.
• Setting: at home, by the patient, a caregiver, or a visiting nurse after training.
• Common side effects: local reactions at the infusion sites (redness, swelling, mild itching, and temporary firmness in the tissue), mainly during the first few infusions; headache and fatigue may occur early and usually ease over time.
• Practical shift: fewer clinic visits each month, with treatment moving from infusion-center days every three weeks to one or two longer sessions at home per month.

Antibody-clearing therapy (subcutaneous)

The second 2024 approval introduced an entirely new class of medicine for CIDP. It marked the first new mechanism of action approved for the condition in over thirty years. Rather than supplying donor antibodies or filtering them from the blood, this therapy blocks a recycling system that normally keeps antibodies circulating for weeks. Blood levels of harmful antibodies fall within days.

• Best suited for: adults with CIDP, particularly when standard treatments are not delivering enough benefit, when IVIG or steroid side effects become a burden, or when getting to infusions has become difficult.
• Approval: adults with CIDP.
• Route: subcutaneous injection under the skin.
• Schedule: once weekly.
• Each session: 30 to 90 seconds, self-administered after training.
• Setting: at home, with no IV line or clinic visit required for the regular weekly dose.
• Evidence: people receiving this therapy were less likely to relapse compared with placebo.
• Common side effects: respiratory and urinary tract infections, headache, and reactions at the injection site.
• Monitoring: doctors watch for signs of infection during follow-up visits because the medicine lowers circulating antibodies broadly.

How the newer treatments compare with standard options

The two 2024 approvals do not replace established treatments. They expand the menu. The right choice depends on a few practical factors that play out differently for each patient.

• Route and time per session: IVIG requires an IV and several hours; standard SCIg is about an hour subcutaneous; the hyaluronidase-facilitated version is longer per session but spaced further apart; the antibody-clearing therapy takes under two minutes once a week.
• Frequency of treatment: standard SCIg weekly; hyaluronidase-facilitated version every two to four weeks; antibody-clearing therapy once weekly; IVIG every three weeks.
• Setting: IVIG and plasma exchange are typically clinic-based; standard SCIg, the hyaluronidase-facilitated version, and the antibody-clearing therapy are home-based after training.
• Side effect patterns: IVIG more often causes systemic effects such as headache, fatigue, and a wash-out feeling; subcutaneous options cause local skin reactions; the antibody-clearing therapy carries an added infection risk because it lowers antibody levels broadly.
• Cost and access: the newer 2024-approved therapies are typically expensive; insurance approval often requires documentation of prior IVIG use; specialty pharmacy programs and copay assistance programs are usually available.

What stays the same across every approved treatment is the goal: reducing the immune attack on the nerves and preventing further nerve damage. None of these treatments is a cure, and ongoing care remains essential to hold on to the progress that treatment buys.

Are these new treatments right for everyone?

The newer treatments are not first-line therapy for every person with CIDP.

• Hyaluronidase-facilitated subcutaneous immunoglobulin is approved as a maintenance therapy for adults whose CIDP is already controlled on IVIG. It is not used as initial treatment.
• Antibody-clearing therapy is approved for adults with CIDP generally, but in practice it tends to come up when standard treatments are not delivering enough benefit, when IVIG or steroid side effects become a real burden, or when getting to infusions has become difficult.
• Neither newer option is a complete replacement for IVIG. IVIG remains the most established first-line therapy with the longest track record. The newer options expand what is available as second-line or maintenance choices, and they may be especially useful for patients whose lives are not well served by clinic-based infusion schedules.

Access matters as much as approval. Distance from a specialty clinic, home nursing availability, insurance coverage, and copay support all shape what is realistic. The 2024 approvals lowered the access barrier by enabling home self-administration, although insurance approval still varies and can take weeks to secure. More on what to do when standard treatments are not working as well as hoped covers this conversation in detail.

Questions patients may wish to discuss with a neurologist

For anyone weighing a treatment change in 2026, a few focused questions can guide the conversation with the neurologist managing CIDP care:

• What is the current treatment actually achieving, and where is it falling short? Honest answers about strength, function, fatigue, and side effects are the starting point for any change.
• Are the newer 2024-approved options a good fit for this case? Approved indications, disease pattern, prior treatment response, and lifestyle all factor in.
• What does the route, schedule, and setting mean for daily life? Clinic time, home time, travel, and family logistics all weigh into the decision.
• What side effects should be expected, and how will they be tracked? Different therapies require different follow-up plans, including more frequent infection monitoring for some options.
• What does insurance actually cover, and what are the out-of-pocket costs? Approval processes, coverage tiers, and copay assistance programs vary widely between treatments.
• How will treatment response be measured, and over what timeline? Clear milestones early on help everyone notice promptly if a change in plan is needed.

Frequently asked questions

How are people managing the time commitment of traditional care versus newer options?

A standard IVIG day usually means several hours at an infusion center, every three weeks. Plasma exchange involves multiple sessions over a few weeks. The 2024 approvals offer a different rhythm. Hyaluronidase-facilitated subcutaneous infusions allow longer intervals between sessions, completed at home. The newer antibody-clearing therapy is under two minutes once a week, also at home. For many people, the shift from clinic-based to home-based treatment is the single biggest practical change in their week.

What is the most effective treatment for CIDP?

There is no single most effective treatment for everyone with CIDP. IVIG, plasma exchange, and steroid medications all have well-established response rates, with roughly six to eight out of every ten people responding well to one of these first-line options. The 2024 approvals add newer options for harder-to-control cases. The most effective treatment for any given person depends on the disease pattern, prior response, side effect tolerance, and personal priorities, which is why treatment decisions are personalized.

Can you fully recover from CIDP?

Recovery from CIDP varies widely. With treatment, many people regain considerable strength and function, sometimes to the point of long stretches of remission. A complete return to pre-diagnosis function is not the typical outcome, however. Most patients continue to have some residual symptoms even when the disease is otherwise well controlled: mild weakness, altered sensation, or persistent fatigue may stay in the background. Early diagnosis and prompt treatment improve the chances of better long-term recovery, because untreated nerve damage can become permanent over time.

Can IVIG reverse nerve damage?

IVIG can interrupt the immune attack on the nerves and allow them to recover function, especially when treatment begins before the underlying nerve fibers are permanently damaged. The early effects come from reducing inflammation around the nerves. Longer-term improvement reflects gradual repair of the myelin coating. What IVIG does not do is reverse damage to the axons, which are the long fibers that carry signals within each nerve. Once axons are lost, recovery tends to be incomplete. This is one reason neurologists emphasize starting treatment early.

What is the success rate of IVIG for CIDP?

Roughly six to eight out of every ten people with CIDP respond meaningfully to IVIG, although the depth of response varies. Some people experience near-complete improvement. Others see partial benefit. A smaller group does not respond well to IVIG and may need a different approach. Response is typically reviewed within several weeks of starting therapy, and adjustments to the dose or frequency may follow. Long-term IVIG can lead to sustained disease control for many patients, although the response can change over time.

Where CIDP treatment stands in 2026

For most of the past three decades, CIDP care meant one of three things: immunoglobulin therapy, plasma exchange, or steroid medications. The 2024 approvals have not replaced that foundation, but they have broadened the options. For some patients, the change is the freedom to manage treatment at home. For others, it is a new option when the standard ones have not delivered enough benefit. For most newly diagnosed patients, the starting point still remains IVIG or steroids; the newer therapies enter the conversation later in the journey.

Researchers continue to explore additional ways to manage CIDP. Those interested in learning more can discuss available options with their healthcare provider.

Whatever the treatment plan, a great deal of the daily reality of living with CIDP day to day depends as much on consistent care, physical therapy, and self-management as on any specific medicine. The right plan is the one developed with a neurologist who understands the full picture and is willing to revisit it as the treatment landscape continues to change.